<p>Pitavastatin should be prescribed with caution in patients with predisposing factors for myopathy. These factors include advanced age (&gt;65 years), renal impairment, and inadequately treated hypothyroidism. Increase in serum transaminases have been reported with HMG-CoA reductase inhibitors, including Pitavastatin. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy.</p>